Senator Ernst receiving backlash over recent comment
SIOUX CITY, Iowa (KCAU) — Senator Joni Ernst received national backlash over a controversial comment made at a town hall in Parkersburg on Friday.
Constituents pushed back on Ernst when talking about potential cuts to Medicaid. One attendee commented that the cuts would cause people to die.
To this, Ernst replied, 'Well, we are all going to die.'
Following those comments, the senator made an 'apology video' over the weekend from a cemetery.
The Iowa Democratic Party responded on their social media pages, saying that Ernst's video is *not an apology.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate. One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451. There were no TEAEs related to LFTs in SION-719-treated subjects. The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state. SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily. Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators. Next Steps For SION-719: Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients. Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label. The study will be completed before the Phase 2a trial is initiated. Next Steps For SION-451: Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109. The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients. Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026. In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with approximately $219.2 million in gross proceeds. Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday. Read Next:Photo by Gorodenkoff via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Boston Globe
20 minutes ago
- Boston Globe
What is the Congressional Budget Office? And why is it a target of Trump?
The budget office also projected that by 2034, 10.9 million more people would be uninsured, due to proposed spending cuts to Medicaid and the Affordable Care Act. Related : The bill now Advertisement In the weeks ahead of the CBO's analysis, the White House and Republican leaders have criticized the budget office in an effort to sow doubt in its findings. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Here's what to know about the nonpartisan agency and what the Trump administration has said about it: What is the CBO? The CBO is a nonpartisan agency that helps lawmakers estimate the cost of proposed legislation and provides reports on federal spending. It's led by a director appointed by Congress to a four-year term, with the selection alternating between the House and Senate Budget Committee chairs. The CBO emphasizes that political affiliation plays no role in its hiring process, stating it selects candidates 'solely on the basis of his or her fitness to perform the duties of the position.' Advertisement Is the CBO partisan? CBO hires analysts based on their expertise, not political affiliation. Staff is expected to maintain objectivity and avoid political influence. In evaluating potential employees, the CBO says that for most positions it looks at whether that person would be perceived to be free from political bias. Like other federal employees, the CBO's staff is also prohibited from making political contributions to members of Congress. The CBO's director, Phillip Swagel, served in former Republican President George W. Bush's administration as an economic adviser and as an assistant secretary at the Treasury Department. What has the CBO said in the past about Trump policy? The budget office said in April 2018, during Trump's first term, that tax receipts would reach $27 trillion from fiscal years 2018 to 2024. However, receipts came in about $1.5 trillion higher than the CBO projected and Republican lawmakers have seized on that discrepancy since then. The CBO later reported that revenues were higher than expected because of the 'burst of inflation' during the COVID-19 pandemic in 2021. There was also an increase in economic activity in 'the later years of the period' adding $700 billion. Also, new tariffs added about $250 billion, with other legislation partially offsetting those factors. What Trump and his allies have said about the agency Ahead of the CBO's analysis, Trump slammed the agency in a 'The Democrat inspired and 'controlled' Congressional Budget Office (CBO) purposefully gave us an EXTREMELY LOW level of Growth, 1.8% over 10 years,' Trump wrote. 'I predict we will do 3, 4, or even 5 times the amount they purposefully 'allotted' to us (1.8 percent) and, with just our minimum expected 3 percent growth, we will more than offset our tax cuts (which will, in actuality, cost us no money!),' Trump added. Advertisement In an 'The CBO sometimes gets projections correct, but they're always off every single time when they project economic growth,' Johnson told NBC News. '[The CBO] always underestimate the growth that will be brought about by tax cuts and reduction in regulations,' Johnson added. At a Alyssa Vega can be reached at
Yahoo
30 minutes ago
- Yahoo
Nearly 300 employees out of work after Johnsonville closes packing plant in far south suburbs
MOMENCE, Ill. — A packing plant in the far south suburbs has closed, putting nearly 300 employees out of work. The Momence Packing Company, located at 334 North Street in Momence, was shuttered as of Monday, a spokesperson for Johnsonville, the Wisconsin-based sausage manufacturer, has confirmed. Ground beef sold nationwide possibly contaminated with E. coli The Momence facility was built in 1962 and began producing Johnsonville products in 1995. According to Johnsonville, the closing impacts 274 employees, who were notified Monday and will receive continued pay and benefits for 60 days. 'We made the difficult decision after evaluating how best to optimize our operations network to address current and future growth,' the spokesperson said in a statement. 'The work from this facility will transition to three other production facilities in Wisconsin and Kansas.' Read more: Latest Chicago news and headlines Johnsonville said it plans to demolish the Momence facility by the end of this year. The company also says about 100 new jobs will be created between two of its Wisconsin plants by the third quarter of this year, 20 to 25 new jobs in Sheboygan Falls and 70 to 75 new jobs in Watertown. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
